CDMO business GenScript ProBio and Eutilex Co. Ltd. committed to developing anti-cancer immunotherapy technology jointly announced that the parties entered into strategic collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs in order to achieve win-win cooperation and accelerate the development of global immunotherapy. According to the collaboration agreement, by means of complementary advantages and strong alliances, Eutilex will use GenScript's high-quality one-stop plasmid and virus platform for plasmid and virus process development and manufacturing in its CAR-T programs. Supported by Eutilex's unique immunotherapy technology and GenScript ProBio's experience in plasmid and virus manufacturing, this collaboration will expedite the launch of cell therapy products.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,105 KRW | -0.24% | +1.94% | -37.72% |
05-16 | Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-37.72% | 56.01M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- A263050 Stock
- News Eutilex.Co.,Ltd
- CDMO business GenScript ProBio and Eutilex Co., Ltd. Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for Car-T Programs